Enlivex Therapeutics Ltd. (TLV:ENLV)

Market Cap	89.47M
Revenue (ttm)	n/a
Net Income (ttm)	-44.13M
Shares Out	n/a
EPS (ttm)	-1.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,932
Average Volume	49,507
Open	342.60
Previous Close	349.30
Day's Range	342.60 - 351.00
52-Week Range	309.30 - 682.90
Beta	0.83
RSI	42.47
Earnings Date	Nov 28, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 71
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: ENLV

Financial Performance

Financial numbers in USD